Wedbush Reiterates “Neutral” Rating for Intellia Therapeutics (NASDAQ:NTLA)
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report)‘s stock had its “neutral” rating restated by investment analysts at Wedbush in a research note issued on Monday,Benzinga reports. They currently have a $10.00 price objective on the stock. Wedbush’s price target would suggest a potential upside of 3.41% from the stock’s previous close. A number of other […]
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report)‘s stock had its “neutral” rating restated by investment analysts at Wedbush in a research note issued on Monday,Benzinga reports. They currently have a $10.00 price objective on the stock. Wedbush’s price target would suggest a potential upside of 3.41% from the stock’s previous close. A number of other […]
